BRIEF-Sangamo's genome editing program to transfer to Biogen's spin-off Bioverativ

* Sangamo's genome editing program for hemoglobinopathies to transfer to biogen's spin-off bioverativ
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.